The current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)], the company’s recombinant factor VIII (rFVIII) for the treatment of patients with hemophilia A. The second suite will initially process RIXUBIS [Coagulation Factor IX (Recombinant)], a recombinant factor IX (rFIX) protein for the treatment of adults with hemophilia B and, when operational, will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment BAX 855 upon regulatory approval.
''As a long-standing, established leader in the global hemophilia community, Baxter has focused efforts on improving standards of care for people with hemophilia,'' said Ludwig Hantson, Ph.D., president of Baxter BioScience. ''The opening of the Singapore facility reinforces our continued commitment to expanding access to advanced, high quality treatments for patients around the world.''
The Singapore facility received regulatory approval from the European Medicines Agency in January 2014 for the production of ADVATE. The facility is the third location in the world supporting ADVATE production.